Scientific Advisory Board

David Perlin, PhD


Executive Director and Professor of the Public Health Research Institute at Rutgers

  Director of the Rutgers Regional Biocontainment Laboratory

  Director of Public Health Research Institute of New Jersey

  Fellow at The New York Academy of Sciences

  • Internationally recognized in infectious disease research and plays a major role in advancing the national research agenda in biodefense and emerging infectious diseases

    • Primary expertise is in fungal infections, mechanisms of antifungal drug resistance, and rapid diagnosis of opportunistic drug resistant bacterial and fungal pathogens in high risk patients

    • Served as a consultant to the U.S Senate Finance Committee’s investigations of the 2001 anthrax outbreak

    • Served as a consulting Microbiologist for the New Jersey Environmental Clearance Committee, which oversaw anthrax cleanup

    • Serves on the editorial board of several scientific journals and serves on the Board of directors of the Aaron Diamond AIDS Research Center, and Scientific/Medical Advisory Boards for the CLSI, LIFE, GAFFI, pharma and biotech companies, and PinnacleCare

    • Helped establish the Public Health Research Institute as a leading tuberculosis and opportunistic infections research organization


  • Published over 185 papers and is the co-author of 2 books

        Lectures on the global impact of infectious diseases and regularly comments in mainstream media outlets,

        such as the New York Times

Jeffrey Henderson, PhD, MD


Assistant Professor of Medicine and Molecular Microbiology

Division of Infectious Diseases

Washington University School of Medicine

  • Physician-Scientist engaged in basic translational research , patient care and teaching


  • Founder of The Henderson Laboratory

    • Uses a multidisciplinary approach to better understand bacterial virulence and devise improved antibacterial therapeutic strategies

    • Uses both chemical biology and microbiological approaches with an emphasis on mass spectrometry, metabolomics, bacterial biofilm culture, bacterial genetics, and disease models

    • Laboratories work is suggesting new therapeutics and diagnostic strategies to improve bacterial infectious disease management


  • Specialties:

    • Infectious Diseases

    • Microbial Pathogenesis

    • Chemical Biology

    • Biochemistry


  • Mass Spectrometry

David Andes, MD


Departments of Medicine, Division of Infectious Diseases and Medical Microbiology and Immunology

  • Heads the Division of Infectious Disease


  • Director off the Infectious Disease Fellowship Program


  • The focus of his research involves identification strategies to combat antimicrobial (especially antifungal) drug resistance


  • Specialties:

    • General infectious diseases

    • Transplant infectious diseases

    • Mycology

    • Antimicrobial Pharmacokinetics and Pharmacodynamics

Nathan Keller, M.D., Ph.D., EMBA


Sheba Medical Center

Director of Clinical Biology

Head of the Laboratory Center

  • Extensive research experience in Infectious Disease and Antibiotic Resistance


  • MD, Hebrew University, Jerusalem, Hadassah Medical School


  • PhD, Medical Microbiology, State University, Utrecht, The Netherlands


  • Graduate, Executive MBA at Tel Aviv University- Kellogg, Northwestern University Chicago, USA


  • Advisory Board, Pfizer Israel and BMS Israel


  • His work has been acknowledged by awards throughout the years for various studies


  • More than 60 original scientific articles published in well-known medical journals